Prognostic Value and Reproducibility of Pretreatment CT Texture Features in Stage III Non-Small Cell Lung Cancer

被引:159
作者
Fried, David V. [1 ,2 ]
Tucker, Susan L. [5 ]
Zhou, Shouhao [3 ]
Liao, Zhongxing [4 ]
Mawlawi, Osama [2 ]
Ibbott, Geoffrey [1 ,2 ]
Court, Laurence E. [1 ,2 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Radiat Phys, Houston, TX 77030 USA
[2] Univ Texas Hlth Sci Ctr Houston, Grad Sch Biomed Sci, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Div Quantitat Sci, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA
[5] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2014年 / 90卷 / 04期
关键词
TUMOR HETEROGENEITY; SURVIVAL; DISCUSSIONS; TOMOGRAPHY; PHYSICIANS; RADIATION;
D O I
10.1016/j.ijrobp.2014.07.020
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To determine whether pretreatment CT texture features can improve patient risk stratification beyond conventional prognostic factors (CPFs) in stage III non-small cell lung cancer (NSCLC). Methods and Materials: We retrospectively reviewed 91 cases with stage III NSCLC treated with definitive chemoradiation therapy. All patients underwent pretreatment diagnostic contrast enhanced computed tomography (CE-CT) followed by 4-dimensional CT (4D-CT) for treatment simulation. We used the average-CT and expiratory (T50-CT) images from the 4D-CT along with the CE-CT for texture extraction. Histogram, gradient, co-occurrence, gray tone difference, and filtration-based techniques were used for texture feature extraction. Penalized Cox regression implementing cross-validation was used for covariate selection and modeling. Models incorporating texture features from the 33 image types and CPFs were compared to those with models incorporating CPFs alone for overall survival (OS), local-regional control (LRC), and freedom from distant metastases (FFDM). Predictive Kaplan-Meier curves were generated using leave-one-out cross-validation. Patients were stratified based on whether their predicted outcome was above or below the median. Reproducibility of texture features was evaluated using test-retest scans from independent patients and quantified using concordance correlation coefficients (CCC). We compared models incorporating the reproducibility seen on test-retest scans to our original models and determined the classification reproducibility. Results: Models incorporating both texture features and CPFs demonstrated a significant improvement in risk stratification compared to models using CPFs alone for OS (P = .046), LRC (P = .01), and FFDM (P = .005). The average CCCs were 0.89, 0.91, and 0.67 for texture features extracted from the average-CT, T50-CT, and CE-CT, respectively. Incorporating reproducibility within our models yielded 80.4% (+/- 3.7% SD), 78.3% (+/- 4.0% SD), and 78.8% (+/- 3.9% SD) classification reproducibility in terms of OS, LRC, and FFDM, respectively. Conclusions: Pretreatment tumor texture may provide prognostic information beyond that obtained from CPFs. Models incorporating feature reproducibility achieved classification rates of similar to 80%. External validation would be required to establish texture as a prognostic factor. (C) 2014 Elsevier Inc.
引用
收藏
页码:834 / 842
页数:9
相关论文
共 50 条
[21]   Value of prognostic nutritional index in patients with non-small cell lung cancer [J].
Kabadayi, Feyyaz ;
Akbay, Makbule Oezlem ;
Akturk, Ulkue Aka ;
Ernam, Dilek .
EURASIAN JOURNAL OF PULMONOLOGY, 2023, 25 (02) :107-115
[22]   Prognostic value of Transglutaminase 2 in non-small cell lung cancer patients [J].
Zhu Chihong ;
Ling Yutian ;
Wan Danying ;
Jiang Ruibin ;
Sheng Huaying ;
Gu Linhui ;
Feng Jianguo .
ONCOTARGET, 2017, 8 (28) :45577-45584
[23]   Prognostic value of metformin for non-small cell lung cancer patients with diabetes [J].
Xu, Tongbai ;
Li, Dongsheng ;
He, Yuan ;
Zhang, Fuliang ;
Qiao, Man ;
Chen, Yanhua .
WORLD JOURNAL OF SURGICAL ONCOLOGY, 2018, 16
[24]   The prognostic and clinicopathological value of HALP score in non-small cell lung cancer [J].
Li, Qin ;
Chen, Mengqi ;
Zhao, Huaqin ;
Zeng, Jiawei .
FRONTIERS IN IMMUNOLOGY, 2025, 16
[25]   Is durvalumab the solution for unresectable stage III non-small cell lung cancer? [J].
Duma, Narjust ;
Mansfield, Aaron S. .
TRANSLATIONAL CANCER RESEARCH, 2018, 7 :S89-S93
[26]   The Evolving Role of Immunotherapy in Stage III Non-Small Cell Lung Cancer [J].
Perdrizet, Kirstin ;
Cheema, Parneet K. .
CURRENT ONCOLOGY, 2021, 28 (06) :5408-5421
[27]   Extended Surgical Resection in Stage III Non-Small Cell Lung Cancer [J].
Hillinger, Sven ;
Weder, Walter .
CONTROVERSIES IN TREATMENT OF LUNG CANCER, 2010, 42 :115-121
[28]   A Glimpse Into the Future for Unresectable Stage III Non-Small Cell Lung Cancer [J].
Bartolomeo, Valentina ;
Cortiula, Francesco ;
Hendriks, Lizza E. L. ;
De Ruysscher, Dirk ;
Filippi, Andrea R. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05) :1455-1460
[29]   Patterns of care for stage III non-small cell lung cancer in Australia [J].
Parente, Phillip ;
Chan, Bryan A. ;
Hughes, Brett G. M. ;
Jasas, Kevin ;
Joshi, Rohit ;
Kao, Steven ;
Hegi-Johnson, Fiona ;
Hui, Rina ;
McLaughlin-Barrett, Sara ;
Nordman, Ina ;
Stone, Emily .
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 (03) :93-100
[30]   TIME TO TREATMENT IN PATIENTS WITH STAGE III NON-SMALL CELL LUNG CANCER [J].
Wang, Li ;
Correa, Candace R. ;
Hayman, James A. ;
Zhao, Lujun ;
Cease, Kemp ;
Brenner, Dean ;
Arenberg, Doug ;
Curtis, Jeffery ;
Kalemkerian, Gregory P. ;
Kong, Feng-Ming .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 74 (03) :790-795